Linathan

Linagliptin, the active ingredient in Linathan, is a DPP-4 inhibitor presented as an oral dosage form for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control. GNH USA supplies Linathan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linathan is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, either alone or in combination with other antidiabetic agents. - Type 2 diabetes mellitus (monotherapy): provides glycaemic control as a standalone treatment. - Type 2 diabetes mellitus (combination therapy): used together with metformin or other agents to enhance glucose lowering. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports blood‑sugar management when lifestyle measures alone are insufficient.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Urinary tract infection: symptoms of dysuria or frequency. - Back pain: occasional musculoskeletal discomfort. - Dizziness: brief episodes of light‑headedness. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute renal failure: rare but reported in vulnerable patients. - Cardiovascular events: rare cases of myocardial infarction.

Linathan should be used with caution in patients with renal or hepatic impairment, and monitoring is advised for hypoglycaemia when combined with insulin or sulfonylureas. - Renal impairment: assess renal function regularly; dose adjustment is not required but caution is advised. - Hepatic impairment: use with caution; monitor liver enzymes. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels closely. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Linathan may interact with several drug classes; clinicians should review patient medication lists before initiating therapy. Major Interactions (Avoid): - Other DPP‑4 inhibitors: duplicate inhibition may increase adverse‑event risk. - Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise linagliptin plasma concentrations. - Insulin or sulfonylureas: heightened hypoglycaemia risk; avoid uncontrolled combination. Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin exposure; monitor glycaemic response. - Diuretics: monitor renal function as volume changes can affect drug handling. - ACE inhibitors: watch for additive hypotensive effects, especially in volume‑depleted patients.